There is a 15-minute delay in the prices. To check out the live prices, log in to your Ventura account or open one today.
Show figures in :Show figures in :
Data is unavailable
Data is unavailable
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 | FY 2011 | FY 2010 | FY 2009 | FY 2008 | FY 2007 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net worth | 31193.45 | 26706.43 | 23407.78 | 20841.69 | 18326.53 | 15763.00 | 15012.28 | 14229.19 | 12543.66 | 11516.22 | 10801.49 | 10050.35 | 9018.68 | 7638.93 | 6666.13 | 5910.57 | 4347.80 | 3755.17 | 3236.01 |
| Fixed assets | 9895.14 | 9493.61 | 9100.65 | 9621.91 | 9393.77 | 9558.59 | 9546.51 | 9949.14 | 9490.24 | 9368.32 | 6829.64 | 6496.47 | 3609.97 | 3215.49 | 3094.18 | 2011.17 | 1992.49 | 1661.36 | 1388.07 |
| Debt | 92.10 | 247.02 | 520.36 | 824.14 | 1755.56 | 2816.43 | 4316.23 | 4098.05 | 4112.66 | 5201.92 | 1703.33 | 1247.91 | 967.07 | 29.17 | 571.89 | 5.07 | 940.24 | 540.45 | 123.56 |
View detailed balance sheet
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 | FY2008 | FY2007 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 5004.98 | 4133.91 | 3237.65 | 3325.90 | 3755.20 | 3068.45 | 1691.14 | 1462.76 | 2381.76 | 1740.81 | 1173.43 | 1563.31 | 1397.67 | 1712.76 | 1025.10 | 1043.03 | 374.83 | 367.00 | 333.94 |
| Investing | -3691.14 | -2988.03 | -2388.51 | -1871.88 | -2387.18 | 104.04 | -1668.68 | -854.01 | -1310.21 | -4522.63 | -941.15 | -1249.86 | -2062.89 | -965.10 | -908.39 | -562.75 | -580.06 | -674.41 | -484.70 |
| Financing | -1292.79 | -1200.43 | -958.29 | -1599.79 | -1239.51 | -2948.82 | -348.72 | -385.48 | -1325.68 | 3104.06 | 164.78 | -265.63 | 717.77 | -753.17 | -82.80 | -471.61 | 178.92 | 254.83 | 238.56 |
Cipla develops, manufactures and markets a wide range of branded and generic medicines and APIs across multiple therapies. Its portfolio covers 50+ dosage forms and 1,500+ products.
Cipla operates 46 manufacturing sites and serves 74 markets globally. It holds leading ranks in India, South Africa and US generic inhalation prescriptions.
The five pillars are One‑India, North America, One Africa, Emerging Markets & Europe, and API, contributing 42%, 29%, 14%, 12% and 2% of revenue respectively.
